11:47 AM EST - Oncolytics Biotech Inc. : announced that it has completed patient enrollment in a Phase 2 clinical trial evaluating intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours. Oncolytics Biotech Inc.
shares T.ONC are trading down $0.10 at $3.45.
